Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Group 1 - Xilio Therapeutics held a conference call to discuss key data updates presented at the Society for Immunotherapy of Cancer (SITC) conference [2][3] - The call featured participation from key executives including the CEO, Chief Medical Officer, and Chief Financial and Operating Officer, along with clinical investigators from the Vilastobart study [3] Group 2 - Details of the SITC presentation can be found in press releases on Xilio's Investor Relations section of their website [2]